Title : The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.

Pub. Date : 2022 Feb 2

PMID : 35159041






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Ibrutinib was the first irreversible BTK inhibitor approved by the U.S. Food and Drug Administration in 2013 as a breakthrough therapy in CLL patients. ibrutinib Bruton tyrosine kinase Homo sapiens
2 Two other irreversible, second-generation BTK inhibitors, acalabrutinib and zanubrutinib, were developed to reduce ibrutinib-mediated adverse effects. ibrutinib Bruton tyrosine kinase Homo sapiens